A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site.
Sponsor: University of Pittsburgh
You may qualify if…
- ✓ 1. Aged ≥ 18 years
- ✓ 2. Kidney Disease Improving Global Outcomes (KDIGO) Stage 2/3 AKI with evidence of persistent AKI (defined as meeting Stage 2+ AKI for 2 consecutive days with serum creatinine concentration measurements \>12 hours apart)
You may not qualify if…
- ✕ 1. AKI due to primary glomerulonephritis, renal vasculitis, or thrombotic microangiopathy
- ✕ 2. Diagnosis of end-stage kidney disease (ESKD) at the time of admission, defined as:
- ✕ 1. Baseline estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73m2
- ✕ 2. Previous kidney transplant recipient
- ✕ 3. On chronic dialysis
- ✕ 3. Acute urinary obstruction with rapid kidney function improvement following relief of obstruction
- ✕ 4. Index hospitalization involving nephrectomy
- ✕ 5. Index hospitalization involving solid organ transplant or stem cell/bone marrow transplant
Where it's recruiting
Source: ClinicalTrials.gov · NCT05805709 · last updated 2026-09-25